Analysis of Stroke in ATHENA – commentary Commentary
Article Sidebar
Published:
Mar 31, 2011
Main Article Content
Abstract
None
Article Details
How to Cite
Płaczkiewicz, D., & Kleinrok, A. (2011). Analysis of Stroke in ATHENA – commentary. Medycyna Faktow (J EBM), 4(1(10), 65-69. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2550
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Singh D., Cingolani E., Diamond G.A., Kaul S.: Dronedarone for atrial fibrillation. Have we expanded the antiarrhythmic armamentarium? J. Am. Coll. Cardiol. 2010; 55: 1569-1576.
2. Quaglino D., Ha H.R., Duner E. et al.: Effects of metabolites and analogs of amiodarone on alveolar acrophages: structure-activity relationship. Am. J. Physiol. Lung. Cell. Mol. Physiol. 2004; 287: L438-447.
3. White H.D., Gruber M., Feyzi J. et al.: Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control. Results from SPORTIF III and V. Arch. Intern. Med. 2007; 167: 239-245.
4. Antonucci E., Grifoni E., Abbate R. et al.: Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J. Am. Coll. Cardiol. 2009; 54: 999-1002.
5. Connolly S.J., Ezekowitz M.D., Yusuf S. et al.: RE-LY Steering Committee and Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009; 361: 1139-1151.
6. Connolly S.J., Eikelboom J., Joyner C. et al.: Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 2011 [online: DOI:10.1056/NEJMoa1007432].
7. Medi C., Hankey G.J., Freedman S.B.: Stroke Risk and Antithrombotic Strategies in Atrial Fibrillation. Stroke 2010; 41; 2705-2713.
8. Draskovich C.D., O’Dell K.M.: Dronedarone for atrial fibrillation: An update of clinical evidence. Formulary 2010; 45: 275-283.
9. Le Heuzey J.Y., De Ferrari G.M., Radzik D. et al.: A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J. Cardiovasc. Electrophysiol. 2010; 21: 597-605.
10. Christiansen C.B., Torp-Pedersen C., Køber L.: Efficacy and safety of dronedarone: a review of randomized trials. Expert Opin. Drug. Saf. 2010; 9: 189-199.
11. Camm A.J., Kirchhof P., Lip G.Y.H. et al.: Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA). Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2010; 31: 2369-2429.
12. Wann L.S., Curtis A.B., January C.T. et al.: 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.J. Am. Coll. Cardiol. 2011; 57: 223-242.
2. Quaglino D., Ha H.R., Duner E. et al.: Effects of metabolites and analogs of amiodarone on alveolar acrophages: structure-activity relationship. Am. J. Physiol. Lung. Cell. Mol. Physiol. 2004; 287: L438-447.
3. White H.D., Gruber M., Feyzi J. et al.: Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control. Results from SPORTIF III and V. Arch. Intern. Med. 2007; 167: 239-245.
4. Antonucci E., Grifoni E., Abbate R. et al.: Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J. Am. Coll. Cardiol. 2009; 54: 999-1002.
5. Connolly S.J., Ezekowitz M.D., Yusuf S. et al.: RE-LY Steering Committee and Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009; 361: 1139-1151.
6. Connolly S.J., Eikelboom J., Joyner C. et al.: Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 2011 [online: DOI:10.1056/NEJMoa1007432].
7. Medi C., Hankey G.J., Freedman S.B.: Stroke Risk and Antithrombotic Strategies in Atrial Fibrillation. Stroke 2010; 41; 2705-2713.
8. Draskovich C.D., O’Dell K.M.: Dronedarone for atrial fibrillation: An update of clinical evidence. Formulary 2010; 45: 275-283.
9. Le Heuzey J.Y., De Ferrari G.M., Radzik D. et al.: A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J. Cardiovasc. Electrophysiol. 2010; 21: 597-605.
10. Christiansen C.B., Torp-Pedersen C., Køber L.: Efficacy and safety of dronedarone: a review of randomized trials. Expert Opin. Drug. Saf. 2010; 9: 189-199.
11. Camm A.J., Kirchhof P., Lip G.Y.H. et al.: Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA). Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2010; 31: 2369-2429.
12. Wann L.S., Curtis A.B., January C.T. et al.: 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.J. Am. Coll. Cardiol. 2011; 57: 223-242.